SCHEMBL3540630

SCHEMBL3540630

CC(=O)C(CC(=O)OCc1ccccc1)NC(=O)c1ccc(-c2ccc(C(=O)NC(CC(=O)OCc3ccccc3)C(C)=O)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.54
MAPT P10636 2/20 0.54
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
TP53 P04637 1/20 0.52
HPGD P15428 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HPGDS O60760 3/20 0.50
CTSB P07858 4/20 0.49
CTSS P25774 2/20 0.49
CTSK P43235 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
MMP9 P14780 1/20 0.47
NPC1 O15118 2/20 0.47
ACE P12821 1/20 0.46
CTSL P07711 1/20 0.46
GAA P10253 1/20 0.46
CYP26A1 O43174 1/20 0.45
TACR1 P25103 1/20 0.44
ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3534617 0.90 MEN1 (0.54) RAB9AMAPTMEN1KMT2ATP53
SCHEMBL3537933 0.88 GPR132 (0.51) RAB9AHPGDSMMP9ACECTSL
SCHEMBL5673271 0.84 TACR1 (0.53) MEN1KMT2AHPGDL3MBTL1MMP9
SCHEMBL13788325 0.83 ALDH1A1 (0.60) CTSBCTSSCTSKMMP9CTSL
SCHEMBL890103 0.82 ALDH1A1 (0.55) CTSBCTSSCTSKL3MBTL1MMP9
SCHEMBL15996601 0.82 ALDH1A1 (0.55) CTSBCTSSCTSKL3MBTL1MMP9
SCHEMBL25556014 0.79 RAB9A (0.55) RAB9AMAPTMEN1KMT2ATP53
SCHEMBL6048079 0.78 KMT2A (0.47) RAB9AMEN1KMT2AHPGDCTSB
SCHEMBL18803705 0.78 NPC1 (0.59) RAB9AMAPTSMN1; SMN2HPGDSCTSB
SCHEMBL7464416 0.78 CA1 (0.47) RAB9AMAPTMEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816385-B2 Dimeric dicarboxylic acid derivatives, their preparation and use HIGH POINT PHARMACEUTICALS, LLC (US) 2010-10-19 US disclosed
US-20040259950-A1 Novel compounds, their preparation and use HIGH POINT PHARMACEUTICALS, LLC 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259950-A1 Novel compounds, their preparation and use PPARG, PPARA, PPARD RAB9A 3036/4885MAPT 3047/4885MEN1 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.